case_images: PMC11386496_01
case_images: Axial CT images of the lung (5mm slice thickness) before and after initiation of entrectinib. A) Imaging from December 2022 demonstrates dense multifocal opacities with areas of nodularity and interlobular thickening. B) Imaging from July 2023 after 6 weeks of treatment with entrectinib shows a marked decrease in multifocal opacities.
case_images: gr1.jpg
case_images: PMC11386496_01_gr1.jpg
case_images: fig1
case_images: CT chest scans performed in December 2022 demonstrated further progression with increasingly dense consolidations and more nodular-appearing areas in both lungs (Fig. 1A). In July 2023, just 6 weeks after starting treatment, CT scan of the chest showed a marked decrease in ground glass and patchy consolidations, representing a response to treatment (Fig. 1B).
case_images: Hematoxylin and eosin stain (at 100X original magnification) shows invasive non-mucinous adenocarcinoma.
case_images: gr2.jpg
case_images: PMC11386496_01_gr2.jpg
case_images: fig2
case_images: Pathology revealed a TTF-1 and Napsin-A positive invasive adenocarcinoma with lepidic and papillary patterns, consistent with lung origin (Fig. 2).